Worth Buying High Purity Tranexamic Acid with CAS 701-54-2

Name: Worth Buying High Purity Tranexamic Acid with CAS 701-54-2
Brand: Mikem (Shandong) Biopharmaceutical Science and Technology Co., Ltd.
SKU: 2142257772

Shandong, ChinaMikem (Shandong) Biopharmaceutical Science and Technology Co., Ltd.

US$30.00-35.00

1 kg

Product specifications

CAS

Product profile

Customization

Available

CAS No.

701-54-2

Formula

C8h15no2

Model NO.

CAS 701-54-2

EINECS

622-133-9

Type

Synthesis Material Intermediates

Appearance

Liquid

Quality

Industrial

Colour

Colorless

Melting Point

233 °C

Density

1.095±0.06 g/cm3(Predicted)

Boiling Point

300.2±15.0 °C(Predicted)

Molecular Weight

157.21

Transport Package

Drum

Specification

25kg/Drum

Trademark

MIKEM

Origin

Shandong China

Production Capacity

50000kg/Month

Company profile

Mikem (Shandong) Biopharmaceutical Science and Technology Co., Ltd.

Shandong, China

Business Type: Group Corporation CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Flexible customizationNearest Port: Qingdao Port, Tianjin Port, Shanghai PortAverage Response Time: ≤10.09h

AI-Powered supplier vetting

SummaryMikem Chemical is engaged in biobased-material research, development, manufacturing, technical services, and chemical-product sales. It reports inventory capability, quality assurance, five quality inspectors, standardized finished-product inspection instructions, flexible customization, ODM services, and OEM experience with recognized brands. Its export share is stated as 90%, although it has exported for only two years and reports no countries served, overseas agents, warehouse, or showroom. R&D documentation is available for audit and engineers use AutoCAD and Photoshop, but there were no new products in the past year, no patents, no SDK, and only one year of stated R&D engineer experience. Service procedures exist for corrective actions and complaints, but written records are unavailable. No valid manufacturing-capacity contract with related subcontractors and no approved-supplier list were reported. Financial figures are omitted; the provided financial data indicates zero reported operating activity,...

Supplier typeThe registered business scope covers biobased-material technology R&D, technical services, manufacturing and sales of biobased materials, chemical-product sales, and import/export activities. This supports classification as a biobased-material manufacturer and technology-oriented supplier, although the slices do not establish a more specific legal supplier category.

After-Sales capabilityThe supplier has procedures for corrective and preventive actions and customer complaints, but no written records; it also lacks overseas agents or branches, overseas warehousing, and overseas showrooms. Inventory capability and participation in one overseas trade show provide some service support, but the documented service system is incomplete.

Financial creditThe slices report zero operating activity across the stated periods and provide no positive financial-performance evidence; the only nonzero financial indicator shown is a current ratio for the latest period. On the provided evidence, financial credibility cannot be favorably established.

R&D capabilityR&D support includes flexible customization, an engineer responsible for converting customer requirements, audit-ready design input/output/review/verification/validation documents, and AutoCAD and Photoshop capability. However, no new product was reported in the past year, patent count is zero, no SDK is available, and total R&D engineer experience is stated as one year, indicating limited demonstrated innovation output.

Production capacityThe supplier manufactures biobased materials, reports inventory capability, has five quality inspectors, and follows uniform finished-product inspection instructions. However, it lacks a valid contract covering manufacturing capacity with related subcontractors, so production governance has a documented deficiency despite evidence of internal production and quality-control resources.

Customization capabilityFlexible customization is explicitly reported for both design and R&D, with an engineer assigned to convert customer customization requirements and ODM services available. The available design-documentation evidence further supports a structured ability to handle customized projects.

Client casesThe supplier reports OEM service for recognized brands and participation in the FCE Pharma Brazil offline trade show. These are evidence of market-facing experience, but no specific customer names, project outcomes, or case details are provided.